OSUR — OraSure Technologies, Inc.
Is OSUR overbought or oversold? Here is the current MarketMoodz read.
OraSure Technologies, Inc. (OSUR) currently reads Neutral on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Medical Instruments & Supplies) last closed at $3.60. The rating moved from Oversold to Neutral on November 17, 2026.
- Public ratingNeutral (as of November 17, 2026)
- Last close$3.60
- Last changeMoved from Oversold to Neutral on November 17, 2026
- SectorHealthcare
- IndustryMedical Instruments & Supplies
AI analysis
OraSure combines a portfolio of oral‑fluid and point‑of‑care diagnostics with recurring consumable revenue, which positions it to benefit from continued interest in at‑home testing. Financial performance tends to be cyclical and tied to infectious‑disease waves and large institutional contracts, so near‑term revenue visibility is limited. Growth catalysts include new product rollouts, larger distribution agreements and conversion of institutional customers to ongoing consumable purchases. Key challenges are competitive pressure on pricing, potential regulatory risk, and the need for prudent capital management if organic cash flow is insufficient to fund commercialization. Social and research sentiment data are limited, and the broader market tone is moderately constructive, favoring growth and defensive healthcare names—an environment that could compress small‑cap diagnostics multiples absent clear accelerating revenue trends. Overall scenarios range from stabilization and modest upside if new products gain traction to continued volatility and downside if demand normalizes and funding needs rise.
Key factors
- Diversified diagnostics product portfolio (rapid/at‑home tests, specimen collection devices) providing recurring consumables revenue
- At‑home and point‑of‑care testing trends support long‑term demand for lateral flow and oral fluid diagnostics
- Revenue sensitivity to infectious‑disease testing cycles (COVID, HIV, drugs of abuse) creates periodic volatility
- Strategic partnerships and distribution channels can accelerate commercial penetration if executed
- Small‑cap balance sheet and access to capital are important for funding R&D and commercialization
- Market sentiment is currently constructive for growth/healthcare exposure but concentrated on large‑cap defensive names
Risks
- Decline in pandemic‑driven testing demand or failure to replace lost COVID revenue with new products
- Intense competition from other rapid/at‑home test makers, lab networks and alternative sample technologies
- Reimbursement pressure, pricing compression and reduced institutional/government procurements
- Regulatory setbacks or delays for new product approvals and emergency use authorizations
- Liquidity/dilution risk if equity or convertible financings are required to fund operations
- Supply chain or manufacturing disruptions that impede test availability during peak demand
Latest MarketMoodz coverage
See today's live rating, score and targets
Members see the live hourly rating for OSUR — the numeric AI score plus targets and entry zones — while this public page updates nightly.
Start the 14-day trialThis page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.